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Abstract
Background. Previous studies have demonstrated that AST-
120 (Kremezin®), a well-known oral adsorbent, inhibits the
progression of diabetic (DM) and non-DMchronic kidney dis-
ease along with a decrease in oxidative stress. This study was
undertaken to investigate whether AST-120 could reduce oxi-
dative stress and ameliorate the development of nephropathy in
experimental DM rats with normal renal function.
Methods. Rats were injected with diluent (C, n = 16) or
65 mg/kg streptozotocin intraperitoneally (DM, n = 16),
and eight rats from each group were treated with chow
containing 5% AST-120. After 3 months, plasma ad-
vanced oxidation protein products (AOPP) and total mal-
ondialdehyde (MDA) levels, 24-h urinary albumin
excretion, and urinary 8-hydroxy-2′-deoxyguanosine (8-
OHdG) excretion were determined by ELISA. Glomerular
endothelial nitric oxide synthase (eNOS), subunits of nic-
otinamide adenine dinucleotide phosphate (NADPH) oxi-
dase (gp91phox, p47phox and p22phox), and fibronectin
(FN) mRNA and protein expressions were determined by
real-time PCR and western blot, respectively. In addition,
dichlorodihydrofluorescein diacetate (DCF-DA) staining
was performed to detect glomerular reactive oxygen spe-
cies (ROS) production.
Results. Compared to the C group, 24-h urinary albumin
excretion was significantly higher in the DM group (P <
0.01), and AST-120 treatment significantly reduced albu-
minuria in DM rats (P < 0.05). Glomerular eNOS,
gp91phox, p47phox and FN expression were significantly
increased in DM rats compared to C rats, and these in-
creases in DM glomeruli were significantly abrogated by
AST-120 treatment (P < 0.05). The increases in plasma
AOPP and MDA levels as well as renal oxidative stress
in DM rats, assessed by DCF-DA staining and urinary
8-OHdG excretion rates, were also significantly attenuated
by AST-120 treatment (P < 0.05).
Conclusion. In conclusion, the renoprotective effects of
AST-120 in DM nephropathy seem to be associated with
the amelioration of enhanced oxidative stress and FN
expression under diabetic conditions.
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Introduction
Numerous experimental and clinical studies have shown
that oxidative stress plays an important role in the develop-
ment and progression of diabetic nephropathy [1]. High
glucose per se, transforming growth factor (TGF)-β1 and
angiotensin II (AII) are all reported to increase reactive
oxygen species (ROS) in cultured mesangial cells, which
in turn activates protein kinase C (PKC) and nuclear factor
(NF)-κB [2–4]. In addition, pathologic changes in glo-
meruli and an increase in urinary albumin excretion in
diabetic rats were ameliorated by dietary antioxidant sup-
plementation with vitamin E, taurine or lipoic acid, sup-
porting the role of oxidative stress in the pathogenesis of
diabetic nephropathy [5–7].
The degree of oxidative stress is determined by the
balance between the production of ROS and the antioxidant
defence system [8]. In experimental and human diabetes,
ROS generation is known to be increased via multiple
pathways, including glucose auto-oxidation, increased mi-
tochondrial superoxide production, PKC-dependent activa-
tion of nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, uncoupled endothelial nitric oxide
synthase (eNOS) activity, formation of advanced glycation
end products (AGEs) and stimulation of cellular ROS pro-
duction by extracellular AGEs through their receptors
[1,9]. Among these, the activation of NADPH oxidase
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and uncoupling of eNOS mainly contribute to the increase
in glomerular superoxide production in experimental dia-
betic rats [10].
AST-120 (Kremezin®, Kureha-Chemical Co., Tokyo,
Japan) is a well-known oral adsorbent which binds and
prevents absorption of several biologically active sub-
stances such as indole from the gastrointestinal tract
[11]. Indole is a precursor of indoxyl sulphate, a well-
known uraemic substance, and serum indoxyl sulphate
concentrations are increased in patients with decreased re-
nal function [12]. In animal and human studies of renal
failure, a close relationship between indoxyl sulphate and
oxidative stress has been found [13,14]. Moreover, previ-
ous studies have shown that AST-120 treatment inhibits the
progression of diabetic [15,16] and non-diabetic chronic
kidney disease [17,18] along with decreased oxidative
stress [13,19,20]. On the other hand, AST-120 is known
to adsorb AGEs such as (carboxymethyl)lysine (CML)
[21], which are not only important mediators in the path-
ogenesis of diabetic nephropathy but also associated with
oxidative stress, both in vivo and in vitro [22,23], suggest-
ing that AST-120 may exert a beneficial effect on diabetic
nephropathy.
To date, however, the effect of AST-120 on non-uraemic
diabetic kidney disease has never been explored. The
present study was undertaken to investigate whether
the administration of an oral adsorbent, AST-120, could
reduce oxidative stress and ameliorate the development
of nephropathy in experimental diabetic rats with normal
renal function in terms of extracellular matrix (ECM)
accumulation.
Materials and methods
Animals
All animal studies were conducted under an approved protocol. Thirty-two
male Sprague–Dawley rats, weighing 250–280 g, were studied. Half were
injected with diluent (control, C) and half with 65 mg/kg streptozotocin
(diabetes, DM) intraperitoneally. Blood glucose levels were measured 3
days after streptozotocin injection to confirm the development of diabetes.
Control and diabetic rats were then randomly assigned to two groups. One
group, composed of eight control and eight diabetic rats, was fed with
standard laboratory chow containing 5% AST-120 (Kremezin®), and the
other group (8 control and 8 diabetic rats) with standard laboratory chow.
All rats were housed in a temperature-controlled room and were given free
access to water and chow during the 3-month study period.
Body weights were checked monthly, and kidney weights were measured
at the time of sacrifice. Serumglucosewasmeasuredmonthly, and blood urea
nitrogen, creatinine and 24-h urinary albumin were determined by ELISA
(Nephrat II, Exocell, Inc., Philadelphia, PA, USA) at the time of sacrifice.
Isolation of glomeruli
Glomeruli were isolated by sieving. Purity of the glomerular preparation
was >98% as determined by light microscopy.
Isolation of total RNA
Total glomerular RNAwas extracted as described previously [24]. Briefly,
100 μl of RNA STAT-60 reagent (Tel-Test, Inc., Friendswood, TX, USA)
was added to the glomeruli, followed by lysis by freezing and thawing
three times. Another 700 μl of RNA STAT-60 reagent was added, the mix-
ture was vortexed and stored for 5 min at room temperature, 160 μl of
chloroform was added and the mixture was shaken vigorously for 30 s.
After 3 min, the mixture was centrifuged at 12 000 g for 15 min at 4°C,
and the upper aqueous phase containing the extracted RNA was trans-
ferred to a new tube. RNA was precipitated from the aqueous phase with
400 μl isopropanol and pelleted by centrifugation at 12 000 g for 30 min
at 4°C. The RNA precipitate was washed with 70% ice-cold ethanol, dried
using a Speed Vac and dissolved in diethyl pyrocarbonate (DEPC)-treated
distilled water. Glomerular RNAyield and quality were assessed based on
spectrophotometric measurement at wavelengths of 260 and 280 nm.
Reverse transcription
First strand cDNA was made using a Boehringer Mannheim cDNA syn-
thesis kit (Boehringer Mannheim GmbH, Mannheim, Germany). Two
microgram of total RNA extracted from sieved glomeruli was reverse
transcribed using 10 μM random hexanucleotide primer, 1 mM dNTP,
8 mM MgCl2, 30 mM KCl, 50 mM Tris–HCl, pH8.5, 0.2 mM dithio-
threitol, 25U RNAse inhibitor and 40U avian myeloblastosis virus (AMV)
reverse transcriptase. The mixture was incubated at 30°C for 10 min and
42°C for 1 h, followed by enzyme inactivation at 99°C for 5 min.
Real-time PCR
Using the ABI PRISM® 7700 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA), PCR was performed in a total volume of
20 μl per well, containing 10 μl SYBR Green® PCR Master Mix (Applied
Biosystems), 5 μl cDNA and 5 pmol sense and antisense primers for
eNOS, NADPH oxidase (gp91phox, p47phox and p22phox), fibronectin
and 18S. Primer sequences are shown in Table 1. Each sample was run in
triplicate in separate tubes to permit quantification of the gene normalized
to 18S.
After real-time PCR, the temperature was increased from 60°C to 95°C
to construct a melting curve. A control without cDNAwas run in parallel
with each assay. The cDNA content of each specimen was determined
using a comparative threshold cycle (Ct) method with 2
−ΔΔCt. The results
were given as relative expression of a specific gene normalized to the 18S
housekeeping gene. Signals from control glomeruli were considered a rel-
ative value of 1.0.
Western blot analysis
Sieved glomeruli were lysed in sodium dodecyl sulphate (SDS) sample
buffer [2% sodium dodecyl sulphate, 10 mM Tris–HCl, pH6.8, 10%
(vol/vol) glycerol]. Aliquots of 50-μg protein were treated with Laemmli
sample buffer, were heated at 100°C for 5 min and were electrophoresed
at 50μg per lane in a 8–12% acrylamide denaturing SDS–polyacrylamide
gel. To detect dimeric form of eNOS, aliquots of 50-μg protein samples
were treated with Laemmli sample buffer without mercaptoethanol, were
not heated and were electrophoresed in the cold room (low-temperature
SDS–PAGE). The proteins were then transferred to a Hybond enhanced
chemiluminescence (ECL) membrane using a Hoeffer semi-dry blotting
apparatus (Hoeffer Instruments, San Francisco, CA, USA). The mem-
brane was incubated in blocking buffer A (1× PBS, 0.1% Tween-20
and 8% nonfat milk) for 1h at room temperature and incubated overnight
at 4°C in a 1:500 dilution of polyclonal antibody detecting eNOS,
gp91phox, p47phox, p22phox, 4-hydroxy-2-nonenal (4-HNE) (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), fibronectin (Chemicon
International, Inc., Temecula, CA, USA) or β-actin (Santa Cruz Biotech-
nology, Inc.). The membrane was then washed once for 15 min and twice
for 5 min in 1× PBS with 0.1% Tween-20 and incubated in buffer A with
horseradish peroxidase-linked goat anti-mouse or anti-rabbit immuno-
globulin G (IgG) (Amersham Life Science, Inc., Arlington Heights, IL,
USA) at 1:1000 dilution. The washes were repeated, and the membrane
was developed with chemiluminescent reagents (ECL; Amersham Life
Science, Inc.). Band densities were measured using TINA image software
(Raytest, Straubenhardt, Germany).
Dichlordihydrofluorescin diacetate (DCF-DA) staining
The fluorescent dye, 2′,7′-DCF-DA (Invitrogen, Carlsbad, CA, USA), was
used to detect the presence of ROS in sieved glomeruli. 2′,7′-DCF-DA
diffuses across cell membranes and is hydrolysed by non-specific cellular
esterases to the non-fluorescent compound dichlorofluorescein (DCFH),
which is trapped predominantly within the cell. In the presence of ROS,
DCFH rapidly undergoes one-electron oxidation to the highly fluorescent
Oral adsorbent in diabetic nephropathy 2135
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compound dichlorofluorescein (DCF). Sieved glomeruli were plated into
two-well Lab-Tek®II Chamber Slides (Nalge Nunc International Corp.,
Naperville, IL, USA) and rinsed with PBS, and the PBS was replaced
with Dulbecco's Modified Eagle's Medium (DMEM) without phenol
red. H2-DCF-DA was dissolved in DMSO to a final 50-mM stock solu-
tion, which was further diluted in DMEM to a final concentration of
50 μM. Glomeruli were then incubated at 37°C for 5 min and subse-
quently rinsed two additional times with DMEM and imaged immedi-
ately. Exposure time was kept at <1 s to avoid photo-oxidation of the
ROS-sensitive dyes and was kept constant for all treatments. At least
three independent fields were chosen for each condition, and 5–10 glo-
meruli in a given field were used to quantify the fluorescence signal.
Formation of DCF was monitored in a fluorescent microplate reader
with emission at 520 nm and excitation at 500 nm. Results were expressed
as fold of control.
Measurement of plasma advanced oxidation protein products (AOPP) and
total malondialdehyde (MDA) levels
Plasma levels of AOPP were determined based on a spectrophotometric
measurement as previously described by Witko-Sarsat et al. [25], and
plasma total MDA concentrations by commercially available kit (Oxis
International, Inc., Foster City, CA, USA) according to manufacturer's
instructions. For AOPP measurement, 200 μl of plasma diluted 1:5 with
PBS, 200 μl of chloramines-T (0–100 μmol/l) for calibration and 200 μl
of PBS as blank were applied on a 96-well microtitre plate. Then, 10 μl of
1.16M potassium iodide and 20 μl of acetic acid were added, and the
absorbance of the reaction mixture was immediately read using a micro-
plate reader at a wavelength of 340 nm. For total MDA, 210 μl of plasma
or serial dilution of tetraethoxypropane as standard, 11 μl of butylated hy-
droxytoluene and 5.3 μl of concentrated HCl were applied on microfuge
tubes and were incubated at 60°C for 80 min. After cooling to room tem-
perature, 680 μl of diluted R1 (N-methyl-2-phenylindole in acetonitrile)
was added, and the mixtures were centrifuged at 13 000 g for 5 min. After
centrifugation, the supernatants were transferred to new tubes. Then, 115 μl
of HClwas added, incubated at 45°C for 60 min and centrifuged at 13 000 g
for 5 min. Total MDA levels in the supernatant were determined based on
spectrophotometric measurement at a wavelength of 586 nm.
Measurement of urine 8-hydroxydeoxyguanosine (8-OHdG) levels
Urine specimens were centrifuged at 1500 rpm for 10 min to remove par-
ticulates (Eppendorf Centrifuge 5415R, Hamburg, Germany). The super-
natants were used, and 8-OHdG levels were measured by using a
competitive in vitro enzyme-linked immunosorbent assay (ELISA) kit
(Bioxytech, OXIS Health Products, Inc., Portland, OR, USA). A 50-μl
urine sample and 50 μl of reconstituted primary antibody were added to
each well of 8-OHdG-coated microtitre plates and incubated at 37°C for
1 h. Plates were washed three times with phosphate-buffered saline, and
horseradish peroxidase-conjugated secondary antibody was added. After
incubation at 37°C for 1h, unbound secondary antibody was removed,
and the plate was washed again three times. The amount of antibody bound
to the plate was determined by the development of colour intensity after the
addition of a substrate containing 3,3′,5,5′-tetra-methyl-benzidine. The re-
action was terminated by the addition of phosphoric acid, and the absor-
bance was measured using a computer-controlled spectrophotometric
plate reader at a wavelength of 450 nm. The concentration of 8-OHdG
was interpolated from a standard curve drawn with the assistance of loga-
rithmic transformation. The detection range of the ELISA assay was 0.5–
200 ng/ml.
Measurement of serum indoxyl sulphate and AGE concentrations
Serum indoxyl sulphate concentrations were measured by high-perfor-
mance liquid chromatography (HPLC). Serum samples (10 μl) were ana-
lysed for 10 min with a mobile phase, 5% tetrahydrofuran/0.1M KH2PO4
(pH6.5), at a flow rate of 1 ml/min and with fluorescence detection with
excitation at 295 nm and emission at 390 nm.
The concentrations of AGEs in serum were determined using a com-
mercial ELISA kit (Uscnlife Sciences & Technology Co., Ltd, Wuhan,
China) according to the manufacturer's protocol. Briefly, 100 μl of stan-
dard solution or sample was added into a 96-well microplate coated with
anti-rat AGEs antibody and incubated at 37°C for 2h. After removal of
solution, 100 μl of detection reagent A solution was added to each well
and incubated at 37°C for 1 h. Plates were washed three times with wash
buffer, and 100 μl of detection reagent B solution was added. After an-
other 1-h incubation at 37°C and four washes, addition of 90 μl of sub-
strate solution was followed by a 30-min incubation at 37°C and in the
dark. Finally, 50 μl of stop solution was added, and the optical density was
determined at 450 nm using an ELISA microtitre plate reader. The kit for
rat AGEs was species-specific, and the minimum detectable concentration
was typically <1.95 ng/ml.
Statistical analysis
All values are expressed as the mean ± standard error of the mean (SEM).
Statistical analyses were performed using the statistical package SPSS for
Windows version 11.0 (SPSS, Inc., Chicago, IL, USA). Results were ana-
lysed using the Kruskal–Wallis non-parametric test for multiple compar-
isons. Significant differences by the Kruskal–Wallis test were confirmed
by the Mann–Whitney U-test. P-values <0.05 were considered statistically
significant.
Results
Animal data
All animals gained weight over the 3-month experimental
period, but weight gain was highest in C rats (P < 0.01).
The ratios of kidney weight to body weight were signifi-
cantly higher in DM (1.34 ± 0.09%) and DM + AST-120
rats (1.28 ± 0.10%) than in C (0.62 ± 0.04%) and C +
AST-120 rats (0.64 ± 0.06%) (P < 0.01). The mean blood
glucose levels of C, C + AST-120, DM and DM + AST-120
rats were 106.4 ± 5.7, 110.5 ± 4.2, 495.0 ± 8.9 and 482.6 ±
6.3 mg/dl, respectively (P < 0.01). The mean creatinine
clearance was higher in DM (6.18 ± 0.97 ml/min/kg body
weight) and DM + AST-120 rats (5.98 ± 0.74 ml/min/kg
body weight) relative to C rats (4.23 ± 0.58 ml/min/kg
body weight) but did not reach statistical significance.
Compared to the C group (0.40 ± 0.06 mg/day), 24-h uri-
nary albumin excretion was significantly higher in the
DM group (1.99 ± 0.17 mg/day, P < 0.01), and AST-
120 treatment significantly reduced albuminuria in DM
rats (1.04 ± 0.19 mg/day, P < 0.05) (Table 2).
Table 1. Sequences of primers used in this study
Name Forward Reverse bp
eNOS GGCTGCTGCCCGAGATATC GGCAGTAATTGCAGGCTCTCA 93
gp91phox CCTGCAGCCTGCCTGAA AAGGAGAGGAGATTCCGACACA 63
p47phox CCGGTGAGATCCACACAGAA TGCACGCTGCCCATCAT 207
p22phox GGTGAGCAGTGGACTCCCATT TGGTAGGTGGCTGCTTGATG 79
Fibronectin TGACAACTGCCGTAGACCTGG TACTGGTTGTAGGTGTGGCCG 72
18S AGTCCCTGCCCTTTGTACACA GATCCGAGGGCCTCACTAAAC 67
2136 S.H. Lee et al.
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Effects of AST-120 on glomerular eNOS, subunits of
NADPH oxidase and fibronectin mRNA expression
Compared to C rats, glomerular eNOS, gp91phox and
p47phox mRNA expression were significantly increased
in DM rats by 2.1-, 3.3- and 2.7-fold, respectively (P <
0.05), and these increases were significantly abrogated
by AST-120 treatment (P < 0.05). In contrast, there was
no difference in glomerular p22phox mRNA expression
among the four groups (Figure 1). Fibronectin mRNA
expression was also increased in DM compared to C glo-
meruli, and AST-120 treatment significantly ameliorated
this increase (P < 0.05) (Figure 1).
Effects of AST-120 on glomerular eNOS, subunits of
NADPH oxidase and fibronectin protein expression
Similar to the mRNA results, glomerular eNOS, gp91phox
and p47phox protein expression assessed by western blot
were significantly increased in DM compared to C rats,
and these increases were significantly attenuated by AST-
120 treatment (P < 0.05). In contrast, there was no differ-
ence in glomerular p22phox protein expression among the
four groups. Fibronectin protein expression was also sig-
nificantly increased in DM glomeruli, and AST treatment
significantly inhibited this increase (P < 0.05) (Figure 2).
To elucidate whether the increase in eNOS protein expres-
sion in DM glomeruli was due to increased eNOS uncou-
pling, Western blot with low-temperature SDS-PAGE was
performed and revealed that uncoupled eNOS protein ex-
pression was increased in DM glomeruli, which was abro-
gated by the administration of AST-120 (Figure 3).
Effect of AST-120 on glomerular ROS production
Glomerular ROS production was evaluated by determining
the fluorescent intensity of DCF. DCF fluorescence inten-
sity was 2.6-fold higher in DM compared to C glomeruli
(P < 0.05), and this increase was significantly ameliorated
by AST-120 treatment (P < 0.05) (Figure 4).
Effects of AST-120 on glomerular 4-HNE protein
expression
The expression of 4-HNE protein complex, which reflexes
ROS-mediated lipid peroxidation [26], was increased in
Table 2. Animal data
C C + AST DM DM + AST
Body weight (g) 557.8 ± 18.8 545.0 ± 15.1 292.1 ± 9.6* 281.3 ± 9.5*
Kwt/Bwt (×10−2) 0.62 ± 0.04 0.64 ± 0.06 1.34 ± 0.09* 1.28 ± 0.10*
Glucose (mg/dl) 106.4 ± 5.7 110.5 ± 4.2 495.0 ± 8.9* 482.6 ± 6.3*
CCr (ml/min/kg Bwt) 4.23 ± 0.58 4.47 ± 0.67 6.18 ± 0.97 5.98 ± 0.74
UAE (mg/day) 0.40 ± 0.06 0.36 ± 0.08 1.99 ± 0.17* 1.04 ± 0.19**
Values are means ± SE.Kwt, kidney weight; Bwt, body weight; CCr, creatinine clearance; UAE, urinary albumin excretion.*P < 0.01 vs. C and C +
AST, **P < 0.05 vs. DM.
Fig. 1. Glomerular eNOS, subunits of NADPH oxidase and fibronectin
mRNA expression assessed by real-time PCR in C, C + AST-120 (AST),
DM and DM + AST groups. Compared to C rats, glomerular eNOS,
gp91phox, p47phox and fibronectin (FN) mRNA/18S rRNA ratios were
significantly increased in DM rats by 2.1-, 3.3-, 2.7- and 2.6-fold,
respectively, and these increases were significantly abrogated by AST-
120 treatment. In contrast, there was no difference in glomerular
p22phox mRNA expression among the four groups. *P < 0.05 vs. C
and C + AST, **P < 0.05 vs. DM, ***P < 0.01 vs. C and C + AST.
Fig. 2. A representative western blot of glomerular eNOS, gp91phox,
p47phox, p22phox, fibronectin (FN) and β-actin in C, C + AST-120
(AST), DM and DM + AST groups (representative of four blots).
Compared to C rats, glomerular eNOS, gp91phox, p47phox and
fibronectin protein expression were significantly increased in DM rats
by 2.4-, 2.0-, 2.3- and 2.5-fold, respectively, and these increases were
significantly ameliorated by the administration of AST-120. In contrast,
there was no difference in glomerular p22phox protein expression
among the four groups. *P < 0.05 vs. C and C + AST, **P < 0.05 vs.
DM, ***P < 0.01 vs. C and C + AST.
Oral adsorbent in diabetic nephropathy 2137
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DM relative to C glomeruli, and AST-120 treatment atten-
uated this increase in glomerular 4-HNE protein expres-
sion in DM rats (Figure 5).
Effect of AST-120 on plasma AOPP and total MDA levels
Plasma concentrations of AOPP and total MDA, which
represent ROS-mediated protein [25] and lipid peroxida-
tion [26], respectively, were significantly increased in
DM (AOPP, 60.6 ± 9.6 μmol/l; MDA, 1.24 ± 0.17 μmol/l)
compared to C rats (AOPP, 31.3 ± 4.5 μmol/l, P < 0.05;
MDA, 0.48 ± 0.07 μmol/l, P < 0.01), and these increases
were significantly inhibited by the administration of AST-
120 (AOPP, 38.9 ± 6.9 μmol/l; MDA, 0.65 ± 0.08 μmol/l)
(P < 0.05) (Figure 6).
Effect of AST-120 on urinary 8-OHdG excretion
Urinary 8-OHdG excretion rates were significantly higher
in DM than C rats (486.9 ± 182.3 vs. 37.3 ± 13.8 ng/kg/h,
P < 0.001), and this increase was significantly abrogated
by AST-120 treatment (151.2 ± 38.4 ng/kg/h) (P < 0.01)
(Figure 7).
Effect of AST-120 on serum indoxyl sulphate and AGEs
concentrations
The mean serum indoxyl sulphate levels of C, C + AST-
120, DM and DM + AST-120 rats were 0.10 ± 0.02, 0.09 ±
0.01, 0.11 ± 0.02 and 0.08 ± 0.01 mg/dl, respectively,
which were comparable among the four groups. In con-
Fig. 4. A representative DCF-DA staining for glomerular ROS
production in C, C + AST-120 (AST), DM and DM + AST groups.
The intensity of DCF fluorescence was 2.6-fold higher in DM
compared to C glomeruli, and this increase was significantly inhibited
by AST-120 treatment. *P < 0.05 vs. C and C + AST, **P < 0.05 vs. DM.
Fig. 3. A representative western blot of eNOS with C, C + AST-120
(AST), DM and DM + AST glomeruli after low temperature SDS–
PAGE electrophoresis (representative of four blots). The expression of
uncoupled eNOS protein was increased in DM relative to C glomeruli,
and AST-120 treatment in DM rats attenuated this increase.
Fig. 5. A representative western blot of glomerular 4-HNE protein
complex in C, C + AST-120 (AST), DM and DM + AST groups
(representative of four blots). The expression of 4-HNE protein was
increased in DM relative to C glomeruli, and AST-120 treatment
abrogated this increase in glomerular 4-HNE protein expression in
DM rats.
Fig. 6. Plasma concentrations of AOPP and total MDA assessed by
ELISA in C, C + AST-120 (AST), DM and DM + AST groups. Plasma
AOPP and MDA levels were significantly higher in DM compared to C
rats, and these increases were signif icantly ameliorated by the
administration of AST-120. *P < 0.05 vs. C and C + AST, **P < 0.01
vs. C and C + AST, ***P < 0.05 vs. DM.
Fig. 7. Urinary 8-OHdG excretion rates assessed by ELISA in C, C +
AST-120 (AST), DM and DM + AST groups. Urinary 8-OHdG
excretion rates were significantly higher in DM compared to C rats,
and this increase was significantly attenuated by AST-120 treatment.
*P < 0.001 vs. C and C + AST, **P < 0.01 vs. DM.
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trast, serum AGEs concentrations were significantly higher
in DM (11.8 ± 2.1 ng/ml) compared to C rats (5.8 ± 0.7 ng/
ml) and C + AST-120 rats (5.3 ± 0.8 ng/ml) (P < 0.05), and
AST-120 treatment significantly ameliorated this increase
(7.0 ± 1.2 ng/ml) (P < 0.05).
Discussion
Recent experimental and clinical studies have demonstrated
that AST-120, an oral absorbent, inhibits the progres-
sion of diabetic [15,16] and non-diabetic chronic kidney
disease [17,18] along with a decrease in oxidative stress
[13,19,20], but the effect of AST-120 on non-uraemic
kidney disease has never been explored. This study de-
monstrates for the first time that AST-120 treatment inhi-
bits the increase in albuminuria and enhanced glomerular
fibronectin expression in diabetic rats. In addition, the re-
sults of this study suggest that reduced oxidative stress
may contribute to these effects of AST-120.
Oxidative stress involves various molecules collectively
called ROS, which include superoxide anions, hydrogen
peroxide, NO, and peroxynitrite and play a pivotal role
in the pathogenesis of diabetic nephropathy [1]. High
glucose increased production of DCF-sensitive ROS in
cultured mesangial cells in a time-dependent manner [2],
and this increase in ROS is known to be dependent on
PKC, NADPH oxidase and the mitochondrial electron
gradient [1–3]. TGF-β1 and AII also increased ROS pro-
duction in cultured mesangial cells in a NADPH oxidase-
dependent manner [3,4]. In addition, ROS are known to
mediate both in vivo and in vitro activation of PKC, NF-
κB, TGF-β1, fibronectin and plasminogen activator inhib-
itor (PAI)-1 under diabetic conditions [2,3,27]. In diabetic
animals, increased activities of glomerular PKC-δ and
PKC- were also inhibited by treatment with taurine, an an-
tioxidant [28]. Similarly, the antioxidant treatment sup-
pressed the increase in glomerular TGF-β1 and
fibronectin mRNA expression, and ameliorated glomeru-
lar thickening, mesangial expansion and proteinuria in
diabetic rats [29,30]. The results of our study show that
fibronectin expression is increased in diabetic glomeruli,
and this increase in fibronectin expression is attenuated
by AST-120 treatment, along with reduced plasma AOPP
and MDA levels, glomerular ROS production and 4-HNE
expression, and urinary 8-OHdG excretion. This suggests
that this change in fibronectin expression is in part medi-
ated by alleviation of enhanced oxidative stress by AST-
120 in diabetic rats.
NADPH oxidase is a major source of oxidants in renal
cells such as tubular epithelial cells and glomerular mesan-
gial cells [31]. NADPH oxidase was originally found in
neutrophils, and it is composed of five subunits: two mem-
brane-associated subunits (gp91phox and p22phox) and
three major cytosolic subunits (p67phox, p47phox and
p40phox) [31]. Under diabetic conditions, the expression
of some subunits of NADPH oxidase is known to be in-
creased in vitro and in vivo, resulting in enhanced oxidative
stress levels [32,33]. Similar to the previous reports, the
present study shows that gp91phox and p47phox mRNA
and protein expression are increased in diabetic glomeruli,
and these increases are ameliorated by AST-120 treatment,
suggesting that AST-120 may reduce oxidative damage in
the diabetic kidney via the inhibition of NADPH oxidase-
mediated ROS production. Among the subunits of
NADPH oxidase, there was no difference in p22phox ex-
pression among the study groups. Even though Kitada et
al. [33] also found no difference in p22phox expression
between control and diabetic glomeruli, the reasons for
the divergence of changes in NAPDH oxidase subunits
are not clear and need to be investigated further.
In addition to NADPH oxidase, increased ROS genera-
tion under diabetic conditions is attributed to changes in
NOS, xanthine oxidase, cyclooxygenase and lipoxygenase
[8]. Particularly, in diabetic nephropathy, the major sources
of ROS are known to be NADPH oxidase and uncoupled
NOS, which reduces glomerular NO production despite in-
creased expression of eNOS [10]. In addition, eNOS itself
is also found to produce O2−, which requires Ca2+/calmod-
ulin and is primarily regulated by tetrahydrobiopterin rath-
er than L-arginine [34]. Although there are conflicting
results on the expression of eNOS in diabetic nephropathy,
many studies have shown that eNOS expression is in-
creased in animal [10,32] and human [35] diabetic glomer-
uli, which is consistent with the findings of this study. In
addition, the results of the present study also show that the
increase in eNOS expression is mainly attributed to the in-
crease in uncoupled eNOS.
The results of this study suggest that AST-120 reduces
oxidative stress in diabetic glomeruli via the inhibition of
NADPH oxidase- and uncoupled eNOS-mediated ROS
production, resulting in decreases in albuminuria and glo-
merular fibronectin expression. However, this leaves us
with another question: how does AST-120 abrogate the up-
regulation of these genes expression under diabetic condi-
tions? AST-120 is an oral adsorbent that consists of fine
spherical carbonic particles of ∼0.2–0.4 mm in diameter
and can absorb low-molecular-weight substances such as
indole [11] which is a precursor of indoxyl sulphate, one
of the well-known circulating uraemic toxins. Recently,
some studies have suggested a close association between
indoxyl sulphate and oxidative stress. AST-120 suppressed
the progression of renal failure in 5/6 nephrectomized rats,
at least in part by the amelioration of oxidative stress as
assessed by urinary excretion of acrolein and 8-OHdG
[19]. In addition, Tumur and Niwa [36] and Muteliefu et
al. [37] found that indoxyl sulphate induced significant
production of ROS in cultured human umbilical vein endo-
thelial cells and cultured human aortic smooth muscle
cells, respectively, via inducing NADPH oxidase expres-
sion. Therefore, we hypothesized that AST-120 may re-
duce indoxyl sulphate levels in diabetic rats, leading to
the attenuation of NADPH oxidase expression and subse-
quently minimizing oxidative stress. However, there was
no difference in serum indoxyl sulphate concentrations
among the study groups. It seems that similar levels of se-
rum indoxyl sulphate are probably due to the comparable
renal function between control and diabetic rats. On the
other hand, AST-120 is also known to adsorb hippuric acid,
p-cresol and AGEs, including methylglyoxal and CML, all
of which are known to be associated with oxidative stress
[21,38]. Since AGEs play an important role in the patho-
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genesis of diabetic nephropathy and induce ROS genera-
tion through stimulation of membrane-bound NADPH ox-
idase [39], we next considered AGEs as candidate
substances responsible for the beneficial effects of AST-
120 and found that serum AGEs concentrations were sig-
nificantly increased in diabetic rats, and this increase was
significantly inhibited by AST-120 treatment. These find-
ings suggest that the inhibitory effect of AST-120 on
NAPDH oxidase expression seems to be partly mediated
by reducing AGEs levels in non-uraemic diabetic rats.
In conclusion, AST-120 treatment alleviates oxidative
stress and abrogates the increase in fibronectin expression
in diabetic nephropathy. These effects seem to be associat-
ed with the amelioration of enhanced NAPDH oxidase and
uncoupled eNOS expression under diabetic conditions.
These findings provide a new perspective on the renopro-
tective effects of AST-120 in diabetic nephropathy.
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Abstract
Background. High blood and tissue concentrations of glu-
cose and advanced glycation end-products (AGEs) are
thought to play an important role in the development of
vascular diabetic complications. Therefore, the impact of
extracellular AGEs and different glucose concentrations
was evaluated by studying the gene expressions and the
underlying cellular pathways involved in the development
of inflammatory pro-atherosclerotic processes observed in
cultured endothelial cells.
Methods. Fresh human umbilical vein cord endothelial
cells (HUVEC) were treated in the presence of elevated
extracellular glucose concentrations (5.5–28 mmol/l) with
and without AGE-human serum albumin (HSA). Affyme-
trix GeneChip® Human Gene 1.0 ST arrays were used for
gene expression analysis (total 20 chips). Genes of interest
were further validated using real-time PCR and western
blot techniques.
Results. Microarray analysis revealed significant changes
in some gene expressions in the presence of the different
stimuli, suggesting that different pathways are involved. Six
genes were selected for validation as follows: thioredoxin-
interacting protein (TXNIP), thioredoxin (TXN), nuclear
factor of kappa B (NF-κB), interleukin 6 (IL6), interleukin
8 (IL8) and receptor of advanced glycation end-products
(RAGE). Interestingly, it was found that the association of
AGEs together with the highest pathophysiological concen-
tration of glucose (28 mmol/l) diminished the expression of
these specific genes, excluding TXN.
Conclusions. In the present model that mimics a diabetic
environment, the relatively short-term experimental condi-
tions used showed an unexpected blunting action of AGEs
in the presence of the highest glucose concentration
(28 mmol/l). The interactive cellular pathways involved
in these processes should be further investigated.
Keywords: advanced glycation end-products; diabetes; endothelial cells;
thioredoxin-interacting protein
Introduction
Diabetes mellitus (DM) is associated with endothelial dys-
function including changes in barrier function and hae-
mostasis, reduced vasodilator responses, inflammatory
activation and increased angiogenesis, as well as more fre-
quent and severe atherosclerotic cardiovascular diseases
[1,2]. Hyperglycaemia is thought to affect endothelial
function, increasing the stiffness of peripheral arteries
and arterioles due, at least in part, to reduced nitric oxide
production [1,2]. The increased formation of AGEs has
been also acknowledged to play a relevant role in the de-
velopment of vascular diabetic complications including
atherosclerosis.
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